ArticleJournal of the International AIDS Society2026
Adding a Prevention Intervention to an Established App: The Blued+ HIV Prevention Pilot Study in Beijing and Chengdu, China.
Article in Journal of the International AIDS Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionHIV incidence among men who have sex with men (MSM) in China remains high, and the use of effective tools such as pre-exposure prophylaxis (PrEP) is suboptimal. Smartphone app interventions are promising yet rarely move beyond the research sphere. Rather than inventing stand-alone apps that rarely come to scale, integrating health interventions into existing multifunction apps would be a paradigm shift for research and practice.
methodsWe conducted a prospective, single-arm pilot study of an intervention platform built directly into Blued, a geosocial networking (dating) app for MSM with more than 6 million users in China. The intervention provided telePrEP care (including in-app clinician services, reimbursed laboratory testing and mailed PrEP prescriptions), health messaging, and an order platform for home HIV tests and condoms. The pilot study, in Beijing and Chengdu, compared the intervention to contemporary repeated cross-sectional comparison surveys. Primary outcomes were benchmarks for feasibility (≥30% home HIV test orders and ≥20% HIV PrEP prescriptions) and acceptability (≥71 System Usability Scale [SUS] score). Preliminary efficacy assessment compared changes in the intervention group to the repeated comparison groups with generalized estimating equations (GEE) models.
resultsFrom July 2022 to December 2024, 423 people started the pilot intervention, 400 (95%) were retained at 6 months and 399 (94%) at 12 months. All primary outcomes at 12 months were significantly higher than prespecified benchmarks: 87% (366/423) ordered HIV tests, 42% (176/423) received PrEP prescriptions, and the mean SUS score was 73/100. In GEE models adjusting for group characteristics and the secular trend of the comparison groups, between baseline and 12 months, the intervention group had an absolute increase in PrEP use of 20% (95% CI: 13%-27%) and in HIV testing of 7% (95% CI: 1%-13%). There was no difference in condom use.
conclusionsIn this study, we found that it is feasible and acceptable to incorporate HIV prevention interventions into existing apps. This model, with encouraging preliminary efficacy data, represents a new public-private model for improving uptake of evidence-based prevention interventions. Future research should test this model in a randomized clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.